Investor Presentaiton
For personal use only
•
Buildout of the Brussels (Seneffe) manufacturing facility
Vertical integration in Europe
Seneffe will serve as the primary EU manufacturing site
for Telix's products
Will also be used to manufacture 131|-based products for export
(i.e. TLX101) using Belgian-sourced isotopes (Belgium is a
major global supplier)
TELIX
PHARMACEUTICALS
Provides certainty / control over supply chain
•
Seneffe will be an integral part of Telix's EU R&D capability
Enables the capture of intellectual property that is intrinsic in
manufacturing scale-up of this class of products
First legacy cyclotron removed October 2021, second in
November 2021
New buildout has commenced
Telix Pharmaceuticals Limited (ASX: TLX)
53
53View entire presentation